Centrica Fair Value Edges Lower, but Fear Has Pushed the Stock Even Further Down

Centrica fair value has slipped, but the sell-off looks sharper

Centrica's implied fair value has moved lower, yet the shares appear to have fallen even further on concern. The core fair value estimate remains around £2.22. JPMorgan's target has also been trimmed in steps, from £2.45 to £2.35, and then to £2.27, even as it maintained an Overweight view. That points to more cautious near-term assumptions rather than a full rejection of the story.

The half-year report triggered the move

On July 23, Centrica reported first-half adjusted EBITDA of £737 million, down from £900 million a year earlier, while adjusted EPS fell to 6.8p and revenue missed expectations. The shares then suffered a 10.18% decline in the immediate reaction.

The sharp drop suggests investors were focused on the headline miss rather than whether the new price already reflected most of the near-term weakness.

Why the current price looks unusually low

Centrica now trades around 163.30p, which sits below the recent analyst target range. That does not prove the stock is cheap, but it does highlight how far sentiment has moved relative to published estimates. JPMorgan still has a £2.35 target, Berenberg £2.30, and the broader fair-value band remains above the current share price.

The key question is no longer whether fair value has improved. It is whether the market has priced in more downside than the current evidence supports.

The first-half disappointment was real, but it does not settle the medium-term case

Lower targets mostly reflect nearer-term earnings pressure. They do not, on their own, show that Centrica's medium-term profit base is permanently damaged.

Results were weak, but management framed the period as transitional

There is no need to soften the interim headline: Centrica delivered adjusted EBITDA of £737 million, down from £900 million a year earlier, and adjusted basic earnings per share edged down to 6.8 pence from 7.0 pence. Revenue was also below expectations.

Management, however, described the backdrop as quite volatile, said Retail profit was slightly higher than a year ago, and said operations were in good shape. At the same time, capex rose to £698 million. That points to a mixed half in which investment and transformation weighed on near-term output.

Medium-term targets still centre on a more stable earnings base

Centrica says it is targeting £1.7bn EBITDA by end-2028, with growth to £2.0bn in 2030 supported by its transformation programme, further investment, and expected nuclear life extensions that are yet to be approved.

That is the real divide in the stock. Bulls see a messy investment phase giving way to a steadier earnings base. Bears see delays in that transition and worry the market is still paying for a plan before execution is clearly visible.

Bulls are betting that the transformation programme will deliver that shift. Bears argue the first-half disappointment was not just bad timing, but a sign that the roadmap is taking longer to show up in reported profit.

What would move the story from debate to proof

After the 10.18% decline following the half-year report, Centrica is no longer getting much benefit of the doubt. Any rerating will need evidence that the strategy is translating into stronger earnings and cash generation, not just a credible long-term narrative.

Signals that would strengthen the case

• Reported results show transformation benefits starting to offset near-term pressure.
• Retail performance and operational stability remain resilient as management has suggested.
• Investment spending continues to support the path toward £1.7bn EBITDA by end-2028.

Signals that would weaken it

• Another weak half shows the transition is dragging on without a clear recovery in earnings quality.
• Revenue and EBITDA disappoint again before the new portfolio mix can start to matter.
• Management's medium-term roadmap keeps getting described as future potential rather than delivered performance.

Fair value is still around £2.22, and some bullish targets still cluster near £2.30. Waiting for clearer proof is reasonable. Waiting too long, though, could mean paying a higher price for the same evidence later.